{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:00Z","timestamp":1790356080776,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03056-5","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:01:46Z","timestamp":1786104106000},"page":"2158-2168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Ami","family":"Jo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3333","authenticated-orcid":false,"given":"Tadahiro","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Musashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Jonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"3056_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"3056_CR2","unstructured":"Cancer Registry and Statistics (JP) (2020) Cancer Information Service [Internet]. National Cancer Center, Tokyo. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/index.html (accessed 1 Aug 2025)"},{"key":"3056_CR3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3802\/jgo.2017.28.e32","volume":"28","author":"W Yamagami","year":"2017","unstructured":"Yamagami W, Nagase S, Takahashi F et al (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32. https:\/\/doi.org\/10.3802\/jgo.2017.28.e32","journal-title":"J Gynecol Oncol"},{"key":"3056_CR4","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200. https:\/\/doi.org\/10.1200\/JCO.2003.02.153","journal-title":"J Clin Oncol"},{"key":"3056_CR5","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S (2022) Epithelial ovarian cancer: Review article. Cancer Treat Res Commun 33:100629. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629","journal-title":"Cancer Treat Res Commun"},{"key":"3056_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"MR Miaja","year":"2020","unstructured":"Miaja MR, Coleman RL, Gonzalez-Martin A et al (2020) The forefront of ovarian cancer therapy: Update on PARP inhibitors. Ann Oncol 31:1148\u20131159. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.004","journal-title":"Ann Oncol"},{"key":"3056_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE et al (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA Cancer J Clin"},{"key":"3056_CR8","unstructured":"National Comprehensive Cancer Network (NCCN) (2025) NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 3. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf (accessed 15 Aug 2025)"},{"key":"3056_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535","journal-title":"N Engl J Med"},{"key":"3056_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2","journal-title":"Lancet Oncol"},{"key":"3056_CR11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"3056_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT et al (2021) Niraparib maintenance therapy using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 32:512\u2013521. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.018","journal-title":"Ann Oncol"},{"key":"3056_CR13","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N et al (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCAm (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22:1721\u20131731. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3","journal-title":"Lancet Oncol"},{"key":"3056_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"3056_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"3056_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.1725","volume":"9","author":"N Li","year":"2023","unstructured":"Li N, Zhu J, Yin R et al (2023) Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial. JAMA Oncol 9:1230\u20131237. https:\/\/doi.org\/10.1001\/jamaoncol.2023.1725","journal-title":"JAMA Oncol"},{"key":"3056_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.06.007","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G et al (2023) Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-Ov38): A phase IIIb trial. Ann Oncol 34:1152\u20131164. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.007","journal-title":"Ann Oncol"},{"key":"3056_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3056_CR19","unstructured":"Japan Clinical Oncology Group (2025) Common Toxicity Criteria for Adverse Events version 5.0 Japanese Translation (CTCAE-JCOG). Available from: https:\/\/jcog.jp\/assets\/CTCAEv5J_20220901_v25_1.pdf (accessed 1 Aug 2025)"},{"key":"3056_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"3056_CR21","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045. https:\/\/doi.org\/10.1200\/JCO.2012.42.0505","journal-title":"J Clin Oncol"},{"key":"3056_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","volume":"22","author":"S Pignata","year":"2021","unstructured":"Pignata S, Lorusso D, Joly F et al (2021) Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: A randomised, phase 3 trial. Lancet Oncol 22:267\u2013276. https:\/\/doi.org\/10.1016\/S1470-2045(20)30637-9","journal-title":"Lancet Oncol"},{"key":"3056_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F et al (2024) ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 35:248\u2013266. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015","journal-title":"Ann Oncol"},{"key":"3056_CR24","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-22-3483","volume":"29","author":"RD Morgan","year":"2023","unstructured":"Morgan RD, Clamp AR, White DJ et al (2023) Multi-maintenance olaparib therapy in relapsed, germline BRCA1\/2-mutant high-grade serous ovarian cancer (MOLTO): A phase II trial. Clin Cancer Res 29:2602\u20132611. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3483","journal-title":"Clin Cancer Res"},{"key":"3056_CR25","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.21873\/anticanres.15961","volume":"42","author":"S Tatsuki","year":"2022","unstructured":"Tatsuki S, Shoji T, Abe M et al (2022) Efficacy and safety of platinum rechallenge in patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: A multicenter retrospective study. Anticancer Res 42:4603\u20134610. https:\/\/doi.org\/10.21873\/anticanres.15961","journal-title":"Anticancer Res"},{"key":"3056_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.21873\/anticanres.16248","volume":"43","author":"M Abe","year":"2023","unstructured":"Abe M, Shoji T, Chiba Y et al (2023) Efficacy and safety of platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance for recurrent ovarian, fallopian tube, and primary peritoneal cancer during PARP inhibitor therapy: A multicenter retrospective study. Anticancer Res 43:1265\u20131272. https:\/\/doi.org\/10.21873\/anticanres.16248","journal-title":"Anticancer Res"},{"key":"3056_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10147-026-02959-7","volume":"31","author":"E Takatori","year":"2026","unstructured":"Takatori E, Shoji T, Jo A et al (2026) Efficacy and Safety of Bevacizumab-Combined Single-Agent Chemotherapy for Platinum-Resistant Ovarian Cancer that Recurred During PARP Inhibitor Treatment. Int J Clin Oncol 31:467\u2013475. https:\/\/doi.org\/10.1007\/s10147-026-02959-7","journal-title":"Int J Clin Oncol"},{"key":"3056_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13048-024-01362-0","volume":"17","author":"H Yuan","year":"2024","unstructured":"Yuan H, Li N, Wu L et al (2024) Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients. J Ovarian Res 17:70. https:\/\/doi.org\/10.1186\/s13048-024-01362-0","journal-title":"J Ovarian Res"},{"key":"3056_CR29","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/cancers15143642","volume":"15","author":"S Dilmac","year":"2023","unstructured":"Dilmac S, Ozpolat B (2023) Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches. Cancers 15:3642. https:\/\/doi.org\/10.3390\/cancers15143642","journal-title":"Cancers"},{"key":"3056_CR30","doi-asserted-by":"publisher","first-page":"1354427","DOI":"10.3389\/fonc.2024.1354427","volume":"14","author":"L Collet","year":"2024","unstructured":"Collet L, Hanvic B, Turinetto M et al (2024) BRCA1\/2 alterations and reversion mutations in the era of PARP inhibitors in high grade ovarian cancer: State of the art and forthcoming challenges. Front Oncol 14:1354427. https:\/\/doi.org\/10.3389\/fonc.2024.1354427","journal-title":"Front Oncol"},{"key":"3056_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P et al (2025) Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer 24:156. https:\/\/doi.org\/10.1186\/s12943-025-02355-1","journal-title":"Mol Cancer"},{"key":"3056_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-024-00451-6","volume":"8","author":"CS Walmsley","year":"2024","unstructured":"Walmsley CS, Jonsson P, Cheng ML et al (2024) Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. NPJ Precis Oncol 8:34. https:\/\/doi.org\/10.1038\/s41698-024-00451-6","journal-title":"NPJ Precis Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03056-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:49:58Z","timestamp":1790354998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03056-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3056"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03056-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8617978\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors of this manuscript has any conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}